Robert D. Siegel

ORCID: 0000-0001-9837-9730 · 1 paper in corpus

article 2004

The Use of Anti-CD20 Chimeric Monoclonal Antibody, Rituximab in Adult Patients with Treatment Refractory Immune Thrombocytopenia.

·doi:10.1182/blood.v104.11.3950.3950

Abstract Introduction: Approximately 20–30% of treated patients with immune thrombocytopenia (IT) will become resistant to standard therapy. Rituximab has been reported to be effective in nearly 50% of such patients. The following report de…